Chromosome 10 is one of the medium-sized human chromosomes, spanning roughly 131.7 million base pairs and housing over 800 protein-coding genes. Several of those genes are heavy hitters in human health: one is the strongest known genetic risk factor for type 2 diabetes, another is among the most frequently lost tumor suppressors across all cancers, and yet another drives an inherited syndrome that can cause thyroid cancer in childhood. When pieces of chromosome 10 are deleted, duplicated, or rearranged, the consequences range from subtle metabolic shifts to severe developmental conditions.
Size, Structure, and Gene Content
The finished sequence of chromosome 10, published in 2004, covers about 131.7 million base pairs representing over 99% of its gene-rich euchromatic DNA. Researchers identified 1,357 genes on the chromosome, of which 816 are protein-coding and 430 are pseudogenes (old gene copies that no longer produce functional proteins).1PubMed. The DNA sequence and comparative analysis of human chromosome 10 That gene count places chromosome 10 solidly in the middle of the pack among human chromosomes, but its medical outsized influence comes from the specific genes it carries rather than sheer numbers.
Chromosome 10 has a short arm (10p) and a long arm (10q), separated by the centromere. Some of the most clinically important genes cluster on the long arm, particularly in the 10q23 region, which is home to both PTEN and the LIPA gene. Other critical genes sit on the short arm, including GATA3 at 10p14. Understanding the geography matters because large deletions or duplications of one arm produce very different clinical pictures depending on which genes are swept up.
PTEN and Cancer
PTEN, located at 10q23, is one of the most commonly disrupted tumor suppressor genes in human cancer. It was discovered in 1997 by two independent research groups studying glioblastoma and prostate cancer cell lines.2PubMed Central. Phosphatases of regenerating liver downregulate PTEN to promote tumorigenesis What makes PTEN unusual is that it works as a phosphatase with dual activity: it can act on both lipids and proteins. Its primary job is to counteract a signaling pathway called PI3K. When PTEN is functioning normally, it keeps the brakes on cell growth, division, and survival. When PTEN is lost or reduced, those brakes come off, and cells become more prone to uncontrolled proliferation.
PTEN loss shows up across an extraordinary range of cancers, including endometrial, breast, prostate, and brain tumors. The gene is considered “dosage-sensitive,” meaning you do not need to lose both copies for trouble to start. Even a partial reduction in PTEN protein levels can tip the balance toward tumor growth.2PubMed Central. Phosphatases of regenerating liver downregulate PTEN to promote tumorigenesis This is part of why PTEN-related cancers are so common: the gene does not need a dramatic knockout to malfunction. Subtle losses, epigenetic silencing, or even interference from other enzymes can erode PTEN’s protective effects incrementally.
Inherited mutations in PTEN also cause a group of conditions collectively called PTEN hamartoma tumor syndrome, which includes Cowden syndrome. People with Cowden syndrome develop multiple noncancerous growths (hamartomas) and face elevated lifetime risks of breast, thyroid, endometrial, and other cancers. Genetic testing for PTEN mutations is now standard for individuals who meet certain clinical criteria, and enhanced cancer screening protocols have been developed specifically for PTEN mutation carriers.
The RET Gene and Multiple Endocrine Neoplasia Type 2
Another gene with major cancer implications on chromosome 10 is RET, which encodes a receptor involved in cell growth and differentiation. Unlike PTEN, which is a tumor suppressor you lose, RET causes trouble when it becomes overactive. Gain-of-function mutations in RET are responsible for multiple endocrine neoplasia type 2 (MEN2), an inherited syndrome that nearly always leads to medullary thyroid carcinoma and can also cause tumors of the adrenal glands (pheochromocytoma) and parathyroid glands.3PubMed. Update multiple endocrine neoplasia type 2
MEN2 follows an autosomal dominant inheritance pattern, meaning a single mutated copy of RET is enough. The syndrome is divided into subtypes, and specific RET mutations predict which organs are most likely to be affected and how aggressively the cancer behaves. These strong genotype-phenotype correlations have made MEN2 one of the best examples in medicine of using genetic testing to guide preventive surgery.4Journal of the Endocrine Society. Update on Multiple Endocrine Neoplasia Type 2: Focus on Medullary Thyroid Carcinoma Children who test positive for high-risk RET mutations are often recommended prophylactic thyroidectomy before the cancer has a chance to develop, sometimes as early as the first year of life for the most aggressive variants.
RET mutations are not limited to inherited syndromes. Somatic RET alterations, including fusions with other genes, also show up in sporadic (non-inherited) cancers of the thyroid and lung. These discoveries have driven the development of targeted therapies, and two RET-specific inhibitors, selpercatinib and pralsetinib, have received FDA approval. Selpercatinib is approved for RET-mutant medullary thyroid cancer, RET-fusion-positive thyroid cancer, and other RET-fusion-positive solid tumors, while pralsetinib covers medullary thyroid cancer, RET-fusion thyroid cancer, and non-small cell lung cancer.5PubMed. FDA-approved RET protein-tyrosine kinase inhibitors in the management of RET-driven thyroid and lung cancer These drugs represented a significant advance because earlier treatments used broader-acting inhibitors that hit many kinases at once, causing more side effects.
Resistance to these targeted therapies remains a challenge. Cancer cells can develop secondary mutations in RET itself, such as the V804L “gatekeeper” mutation, which blocks the drug from binding effectively. Researchers are working on next-generation compounds designed to retain activity against these resistant mutations. One experimental series of compounds has already shown potent activity against both normal RET and the V804L mutant at very low concentrations in laboratory testing.6PubMed Central. Synthesis, and evaluation of novel low nanomolar isoindigo-based RET kinase inhibitors
TCF7L2 and Type 2 Diabetes
If PTEN is the most important cancer gene on chromosome 10, TCF7L2 holds the equivalent title for type 2 diabetes. Located on the long arm of the chromosome, TCF7L2 is the strongest known genetic risk locus for type 2 diabetes, and its association has been confirmed in populations across the world with diverse genetic backgrounds.7PubMed Central. The Role of TCF7L2 in Type 2 Diabetes
The discovery came from a landmark study that identified a variant within the TCF7L2 gene associated with type 2 diabetes at very high statistical significance, confirmed across Icelandic, Danish, and American cohorts. People carrying one copy of the at-risk allele, roughly 38% of the population studied, had about a 45% higher risk of developing the disease, while those carrying two copies (about 7% of the population) faced roughly two and a half times the risk. The population attributable risk was estimated at 21%, meaning this single gene variant accounted for about a fifth of the type 2 diabetes cases in the population.8PubMed. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
Later work in Mexican American populations found that specific combinations of variants (haplotypes) in and around TCF7L2 were associated not only with diabetes risk but also with the age at which diabetes appeared and with blood glucose levels measured after a glucose challenge. Some haplotypes were protective, reducing risk by about 31%, while others increased risk roughly 64%.9PubMed. Haplotypes of transcription factor 7-like 2 (TCF7L2) gene and its upstream region are associated with type 2 diabetes and age of onset in Mexican Americans TCF7L2 encodes a transcription factor involved in the Wnt signaling pathway, which influences how pancreatic beta cells develop and function. When TCF7L2 activity is altered, the body’s ability to produce and secrete insulin in response to rising blood sugar can be impaired. This helps explain why the gene’s influence is so consistent across populations: it acts on a fundamental step in glucose regulation rather than on something population-specific.
HDR Syndrome and the GATA3 Gene
On the short arm of chromosome 10, the GATA3 gene plays a critical role during embryonic development. It belongs to a family of transcription factors that guide the formation of several organ systems, including the parathyroid glands, the inner ear, the kidneys, the thymus, and parts of the central nervous system.10JCEM Case Reports. Hypoparathyroidism, Sensorineural Deafness, and Renal Disease Syndrome Presenting With Febrile Seizures and Hypocalcemia When one copy of GATA3 is lost or carries a disabling mutation, the result is HDR syndrome, a rare autosomal dominant condition characterized by three hallmark features: low parathyroid hormone (hypoparathyroidism), hearing loss, and kidney abnormalities.11PubMed Central. Hypoparathyroidism, sensorineural deafness and renal disease (HDR) syndrome due to a novel GATA3 mutation p.Ala287Asp
The connection between GATA3 and HDR syndrome was established through deletion-mapping studies that narrowed the critical region to about 200 kilobases on 10p. Mutations found in patients included nonsense mutations and deletions that completely abolished the protein’s ability to bind DNA.12PubMed. GATA3 haplo-insufficiency causes human HDR syndrome Not every patient with a GATA3 mutation develops all three features of the triad. Some present initially with unexplained seizures from low calcium (a consequence of hypoparathyroidism) before the hearing loss or kidney problems become apparent. This variability can delay diagnosis, especially in young children.
Other Single-Gene Conditions on Chromosome 10
Beyond the headline genes, chromosome 10 hosts several others linked to specific diseases. The LIPA gene at 10q23.2-23.3 encodes lysosomal acid lipase, an enzyme needed to break down cholesterol esters and triglycerides inside cells. Mutations in both copies of LIPA cause two related conditions: Wolman disease, a severe infantile form that is usually fatal within the first year without treatment, and cholesteryl ester storage disease, a milder form that can present later in life with liver enlargement and abnormal lipid levels.13PubMed Central. Intragenic Deletion as a Novel Type of Mutation in Wolman Disease
The FGFR2 gene, also on chromosome 10, encodes a receptor for fibroblast growth factor. Certain mutations in FGFR2 cause premature fusion of skull bones during development, a condition called craniosynostosis. Depending on which specific mutation occurs, this manifests as Crouzon syndrome, Apert syndrome, or Pfeiffer syndrome, each with characteristic facial features and sometimes hand and foot abnormalities.14PubMed Central. Generation of human induced pluripotent stem cell lines from patients with FGFR2-linked syndromic craniosynostosis
The ERCC6 gene (also known as CSB) is involved in a DNA repair process called transcription-coupled repair. Mutations in ERCC6 cause Cockayne syndrome group B, a condition characterized by sensitivity to sunlight, growth failure, and progressive neurological deterioration.15PubMed Central. The human CSB (ERCC6) gene corrects the transcription-coupled repair defect in the CHO cell mutant UV61 Children with Cockayne syndrome often appear to age prematurely, and the condition is sometimes classified among the progeroid syndromes.
Neurodegeneration With Brain Iron Accumulation
The PANK2 gene on chromosome 20 is the most common cause of neurodegeneration with brain iron accumulation (NBIA), specifically a subtype called pantothenate kinase-associated neurodegeneration, or PKAN.16PubMed Central. Focus on Clinical and Genetic Aspects of PKAN Through the Description of New Patients Though PANK2 itself sits on chromosome 20 rather than chromosome 10, the condition is worth noting because it intersects with broader questions about iron metabolism and neurodegeneration that touch genes on multiple chromosomes, including chromosome 10’s IDE gene.
IDE (insulin-degrading enzyme), located on chromosome 10, is responsible for breaking down both insulin and amyloid-beta protein, the peptide that accumulates in Alzheimer’s disease. Research in animal models has shown that naturally occurring mutations in IDE reduce its ability to clear both insulin and amyloid-beta, raising the possibility that a single enzyme deficiency could link type 2 diabetes and Alzheimer’s risk. In one study, primary neurons from animals with IDE mutations showed significantly elevated levels of amyloid-beta, on the order of 15 to 30% higher than controls.17American Journal of Pathology. Insulin-Degrading Enzyme Regulates the Cadmium Levels of Insulin, Amyloid β-Protein, and the β-Amyloid Precursor Protein Intracellular Domain In Vivo This is still primarily animal-model evidence, and the connection between IDE variants and Alzheimer’s in humans remains an area of active research rather than established fact.
Structural Abnormalities of Chromosome 10
When large sections of chromosome 10 are missing, duplicated, or rearranged, the effects typically involve multiple organ systems because many genes are disrupted simultaneously. These structural changes are rare, but they produce recognizable patterns.
Deletions of the short arm (10p) are among the better-characterized abnormalities. In one reported case, a deletion spanning the region 10p15.3 to 10p12.31, roughly 19.5 million base pairs, led to global developmental delay, distinctive facial features including cleft lip, heart defects, and sensorineural hearing loss.18PubMed Central. Distal trisomy 10q syndrome, report of a patient with duplicated q24.31 – qter, autism spectrum disorder and unusual features Because this region encompasses GATA3, some of the features overlap with HDR syndrome, particularly the hearing loss and kidney abnormalities. But the larger deletion captures many additional genes, producing a broader and more severe clinical picture than GATA3 loss alone.
Extra copies of the distal long arm (distal trisomy 10q) cause a distinct set of problems. Common features include delayed growth and development, low muscle tone, distinctive facial features such as a flat nasal bridge and a bow-shaped mouth, small head circumference, and sometimes cleft palate. Additional reported findings include ear anomalies, foot deformities, and bent fingers (camptodactyly).19PubMed Central. Partial distal 10q trisomy due to de novo amplification: A new case without furrows or ridges in fingers and palms Autism spectrum disorder has been documented in at least one case.18PubMed Central. Distal trisomy 10q syndrome, report of a patient with duplicated q24.31 – qter, autism spectrum disorder and unusual features
Ring chromosomes form when both ends of a chromosome break off and the remaining piece fuses into a circle. Ring chromosome 10 is rare but has been described in a small number of patients, typically presenting with short stature, small head size, facial differences, eye abnormalities such as strabismus, and urogenital malformations. Intellectual disability and developmental delay are nearly universal.20PubMed Central. Expanding the Neurological Phenotype of Ring Chromosome 10 Syndrome: A Case Report and Review of the Literature The severity depends on how much genetic material is lost at the breakpoints. In one case, high-resolution testing revealed that the ring involved a 12.5 million base-pair deletion from the end of the long arm and a smaller 285-kilobase deletion from the short arm tip.21PubMed Central. Chromosome r(10)(p15.3q26.12) in a newborn child: case report
How These Abnormalities Are Detected
For decades, the standard first step in evaluating a child with unexplained developmental delay, intellectual disability, or birth defects was a conventional karyotype, which involves staining and photographing chromosomes under a microscope. This approach can spot large rearrangements but misses smaller deletions and duplications. Chromosomal microarray analysis has replaced traditional karyotyping as the recommended first-line genetic test for these patients. Microarray detects submicroscopic copy-number changes and achieves a diagnostic yield of about 15-20%, compared with roughly 3% for conventional karyotyping (excluding common conditions like Down syndrome that are easily spotted visually).22PubMed Central. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies
This shift matters for chromosome 10 conditions because many of the clinically significant deletions and duplications are too small to see on a standard karyotype. A child with hearing loss, low calcium, and mild kidney changes could have a small deletion at 10p14 involving GATA3 that would be invisible to traditional testing. Microarray picks these up reliably, giving families answers and guiding follow-up care, such as monitoring calcium levels and kidney function in HDR syndrome or implementing early hearing interventions.
The CYP2C Gene Cluster and Drug Metabolism
Chromosome 10 also houses a cluster of four closely related genes, CYP2C8, CYP2C9, CYP2C18, and CYP2C19, that encode enzymes belonging to the cytochrome P450 family. These enzymes are responsible for metabolizing a wide range of commonly prescribed medications, including blood thinners like warfarin, anti-seizure drugs, antidepressants, and proton pump inhibitors used for acid reflux. The four genes are organized into two sub-clusters, and there is a tendency for variants in neighboring genes to be inherited together, which means a person’s ability to metabolize one drug through CYP2C19 can correlate with their metabolism of a different drug through CYP2C9.23Nature Genetics. Haplotype block structure of the cytochrome P450 CYP2C gene cluster on chromosome 10
This has real consequences for prescribing. CYP2C19 “poor metabolizers,” for example, activate the blood thinner clopidogrel (Plavix) less effectively, which can leave them underprotected against blood clots after a heart procedure. CYP2C9 slow metabolizers clear warfarin more slowly, putting them at higher risk of bleeding if given standard doses. Pharmacogenomic testing of these genes is increasingly being used to guide drug selection and dosing in clinical practice, and the fact that these genes cluster together on chromosome 10 means a single genomic region can influence a patient’s response to multiple unrelated medications.
Evolutionary History of Chromosome 10
The current form of human chromosome 10 is not the ancestral arrangement. Studies tracing the chromosome’s evolutionary history across primates found that in the earliest primate ancestors, the short arm (10p) and long arm (10q) existed as parts of separate chromosomes. In the ancestor of prosimians (lemurs and their relatives), what became 10p and 10q were entirely distinct chromosomes. In the ancestor of New World monkeys, 10p remained separate while 10q was joined to material from what became chromosome 16 in humans. It was only in the ancestor of Old World monkeys and apes that the two arms merged into a single chromosome resembling the human form.24PubMed. Evolutionary history of chromosome 10 in primates
This evolutionary patchwork may help explain why deletions of the short arm and deletions of the long arm produce such different clinical pictures: the two arms spent millions of years as functionally independent units before being stitched together. Interestingly, the researchers also documented cases of “centromere repositioning” in some monkey species, where the centromere moved to a different location on the chromosome without any apparent change in gene order, a phenomenon that challenges the assumption that centromere position is fixed once a chromosome’s structure is established.